Nanotechnology-Based Development of a Jembrana Disease
Virus (JDV) Vaccine: A Novel Approach to Protecting Bali Cattle (Bos
javanicus)
ABSTRACT
Jembrana disease is an acute infectious disease of Bali
cattle (Bos javanicus) caused by Jembrana disease virus (JDV), a member
of the genus Lentivirus within the family Retroviridae. The
disease exhibits unusual clinical characteristics compared with most lentiviral
infections in mammals, including high fever, thrombocytopenia, hematological
abnormalities, and a significant risk of mortality. Disease control in
Indonesia has included the use of inactivated tissue-based vaccines, which have
demonstrated benefits in reducing viral load and mitigating the risk of
transmission. However, reliance on animal-derived biological materials, the
need for production standardization, and limitations in protection against
infection highlight the need to develop alternative vaccine platforms. This
article aims to review the potential application of nanotechnology in the
development of next-generation JDV vaccines, particularly through lipid nanoparticles
(LNPs), poly(lactic-co-glycolic acid) (PLGA) nanoparticles, and chitosan-based
nanocarriers. Potential vaccine antigens include envelope glycoproteins,
particularly the surface unit (Env-SU), as well as nonstructural antigens such
as Tat, which require further evaluation in terms of immunogenicity and safety.
Nanodelivery systems may protect antigens or nucleic acids, enhance uptake by
antigen-presenting cells, and support the induction of both humoral and
cellular immune responses. Nevertheless, their ability to enhance
cross-presentation through major histocompatibility complex class I (MHC-I),
prolong antigen release, and provide superior protection against JDV infection
remains to be experimentally demonstrated. Further studies should include
physicochemical characterization, formulation stability, safety assessment, immunogenicity
evaluation, and challenge-protection studies in Bali cattle, in accordance with
applicable ethical and biosafety requirements. Nanotechnology has the potential
to provide a foundation for developing JDV vaccines that are more standardized,
safer, and suitable for sustainable production.
Keywords: Jembrana
disease virus, Bali cattle, nanotechnology, subunit vaccine, lipid
nanoparticles, PLGA, chitosan.
1. INTRODUCTION
Jembrana disease is a contagious disease that primarily
affects Bali cattle and was first recognized in Jembrana Regency, Bali,
Indonesia. The causative agent is Jembrana disease virus (JDV), a
positive-sense, single-stranded RNA virus belonging to the family Retroviridae
and the genus Lentivirus. Although JDV is genetically related to bovine
immunodeficiency virus (BIV), it causes a distinct disease presentation,
particularly due to its acute course of infection in Bali cattle (Desport &
Lewis, 2010).
The clinical manifestations of Jembrana disease include
high fever, enlargement of lymph nodes, thrombocytopenia, hematological
abnormalities, and, in severe cases, death. Reported mortality rates vary
depending on the affected population, outbreak conditions, and characteristics
of the infection. Therefore, the mortality rate of approximately 15–20%, which
is frequently cited, should be interpreted as a range reported under specific
circumstances rather than a universal figure applicable to all disease
outbreaks (Desport & Lewis, 2010).
Controlling this disease is essential to protecting Bali
cattle populations as an important indigenous livestock genetic resource of
Indonesia. In addition to causing economic losses, Jembrana disease outbreaks
can hinder livestock development, animal trade, and programs aimed at improving
the productivity of local cattle breeds.
One control strategy that has been implemented is the use
of inactivated tissue-based vaccines. Hartaningsih et al. (2001) demonstrated
that vaccines produced using virus-containing materials derived from plasma and
spleen tissues, followed by inactivation and formulation with an adjuvant,
could reduce the duration and severity of the disease. However, vaccination
does not completely prevent disease development following viral challenge.
Research by Ditcham et al. (2009) also demonstrated that tissue-based
vaccination could reduce viral loads above the threshold associated with
transmission risk by 96% compared with the control group. These findings
demonstrate the benefits of vaccination while highlighting the need for
continued improvements in disease control effectiveness.
The use of animal-derived biological materials as antigen
sources also presents challenges related to raw material consistency, quality
control, production capacity, and biological safety testing requirements. These
challenges provide a rationale for exploring recombinant subunit vaccines and
nucleic acid-based vaccines that do not require antigen production through the
harvesting of organs from infected animals.
Nanotechnology offers a relevant approach because it can
be used to protect antigens, regulate delivery characteristics, and influence
interactions between antigens and the immune system. Various nanoparticle
platforms have been developed in modern vaccinology, including lipid
nanoparticles (LNPs) for mRNA delivery and polymeric nanoparticles for antigen
formulation. However, the success of these platforms against other diseases
does not automatically establish their effectiveness against JDV.
Against this background, this article reviews strategies
for developing nanotechnology-based JDV vaccines, with particular emphasis on
antigen selection, delivery platforms, immunological mechanisms, product
characterization, and the research stages required before their potential
application in livestock production systems.
2. METHODOLOGY
This article was prepared using a narrative literature
review approach focusing on Jembrana disease, the characteristics of JDV,
inactivated tissue-based vaccines, and advances in nanoparticle-based vaccine
delivery systems. The literature reviewed included experimental studies on JDV
vaccines, review articles on disease pathogenesis and control, and publications
addressing lipid nanoparticles (LNPs) and the stability of mRNA vaccines.
The collected information was analyzed using a
descriptive-comparative approach based on five main aspects: antigen selection,
delivery material characteristics, mechanisms of immune response induction,
potential for large-scale production, and safety and stability challenges.
As this article constitutes a narrative review rather
than an experimental study, no nanoparticle formulation, laboratory testing, or
viral challenge experiments were conducted. Therefore, the potential advantages
of nanotechnology-based vaccines against JDV discussed in this article are
presented as scientifically plausible prospects requiring further validation,
rather than as experimentally demonstrated efficacy outcomes.
3. RESULTS AND DISCUSSION
3.1. Characteristics of JDV and Their Implications for
Vaccine Development
JDV exhibits interesting biological characteristics
because it belongs to the genus Lentivirus yet can cause acute disease
in Bali cattle. Upon entering susceptible cells, the virus undergoes reverse
transcription, converting its RNA genome into DNA, which can subsequently
integrate into the host cell genome as proviral DNA. This process is a defining
characteristic of retroviruses and represents an important consideration in
vaccine platform selection (Desport & Lewis, 2010).
These characteristics have two major implications. First,
an ideal vaccine should induce antibodies capable of inhibiting viral
infection, as well as cellular immune responses that can help control infected
cells. Second, vaccine platforms should avoid the use of replication-competent
live viruses unless their safety has been subjected to rigorous evaluation.
Inactivated vaccines can provide clinical protection;
however, research findings indicate that such protection does not necessarily
translate into complete prevention of infection. Therefore, the performance of
next-generation JDV vaccines should be evaluated using multiple indicators,
including disease severity, duration of fever, viral load, antibody responses,
T-cell responses, and the potential for viral transmission.
The development of nanotechnology-based vaccines should
be guided by these biological requirements rather than solely by the ability to
produce particles within the nanometer range. Particle size represents only one
formulation parameter, whereas vaccine performance depends on the overall
interplay among the antigen, delivery system, immune responses, safety, and
protection against disease.
3.2. Selection of JDV-Specific Target Antigens
Antigen selection is one of the most critical steps in
the development of subunit vaccines and nucleic acid-based vaccines. Two
potential candidates that warrant consideration are envelope glycoproteins and
the regulatory protein Tat.
3.2.1. Envelope Surface Unit (Env-SU)
The Env-SU protein is part of the envelope glycoprotein
complex involved in viral interactions with host cells. Because it is located
on the surface of viral particles, this protein represents a relevant target
for vaccine development aimed at inducing antibodies that may inhibit viral
entry into host cells.
In vaccine development, recombinant Env-SU antigen may be
considered as a subunit protein delivered using polymeric nanoparticles.
Alternatively, mRNA encoding the selected antigen can be delivered through
lipid nanoparticles (LNPs), enabling host cells to produce the antigenic
protein.
However, antigen design must take into account protein
structure, glycosylation, conformation, and the preservation of epitopes
recognized by antibodies. Recombinant proteins that fail to maintain the
appropriate antigenic structure may not necessarily induce effective
neutralizing antibodies.
Therefore, the suitability of Env-SU as a vaccine
candidate should be determined through antigen expression studies, recognition
by specific antibodies, evaluation of its ability to induce neutralizing
antibodies, and assessment of its correlation with protection against disease.
Computational codon optimization may help improve protein expression; however,
it does not, by itself, establish vaccine efficacy.
3.2.2. Tat Protein
Tat is a regulatory protein involved in the regulation of
viral transcription through its interaction with transcriptional regulatory
elements. Its role in JDV replication dynamics makes this protein an
interesting candidate for investigation as a potential source of epitopes for
inducing T-cell responses.
Unlike Env-SU, which is located on the viral surface, Tat
is not a primary target for neutralizing antibodies against free viral
particles. Its potential value is more closely associated with the possibility
of inducing cellular immune responses against antigens expressed within
infected cells.
Nevertheless, the use of Tat as a vaccine component
requires specific assessments of its safety, antigenic form, and ability to
induce relevant immune responses. Protein-based strategies or genetic
constructs must be carefully designed to avoid unintended viral regulatory
activity.
Therefore, the incorporation of Env-SU and Tat into a
single formulation represents a development hypothesis that warrants
experimental investigation, rather than a combination that has already been
demonstrated to provide optimal protection in Bali cattle.
3.3. Nanotechnology Platforms for JDV Vaccines
Two major platform categories warrant consideration:
lipid nanoparticles (LNPs) for nucleic acid delivery and biodegradable
polymeric nanoparticles for protein antigen delivery.
3.3.1. Lipid Nanoparticles for mRNA Vaccines
Lipid nanoparticles (LNPs) are delivery systems that have
been widely used in the development of mRNA vaccines. Their formulations may
include ionizable lipids, helper phospholipids, cholesterol, and polyethylene
glycol (PEG)-conjugated lipids.
Ionizable lipids facilitate nucleic acid encapsulation
and contribute to cargo release from endosomal compartments. Phospholipids and
cholesterol support particle structure and physicochemical properties, whereas
PEG-lipids can influence particle size, colloidal stability, and interactions
with the biological environment.
Conceptually, this platform can be investigated for the
delivery of mRNA encoding selected JDV antigens. Following administration, the
particles may be taken up by cells, including antigen-presenting cells. The
mRNA that successfully reaches the cytoplasm is translated into antigenic
proteins, which can subsequently be processed and presented to immune cells.
Studies on mRNA-LNP vaccines have demonstrated the
potential of this platform to induce both humoral and cellular immune
responses. However, the stability of mRNA and LNPs is influenced by formulation
composition, storage temperature, and distribution conditions. Some mRNA
vaccine formulations require frozen or ultra-low-temperature storage, making
cold-chain stability an important challenge for implementation in remote
livestock farming areas (Schoenmaker et al., 2021).
Therefore, the development of LNPs for JDV vaccines
should consider not only delivery efficiency but also storage stability,
distribution feasibility, cost per dose, and compatibility with Indonesia's
veterinary healthcare delivery systems.
3.3.2. PLGA Nanoparticles for Subunit Vaccines
Poly(lactic-co-glycolic acid) (PLGA) is a biodegradable
polymer that has been extensively investigated for drug and antigen delivery
applications. This material can form nanoparticle matrices that help protect
biological cargo and influence its release characteristics.
For JDV vaccines, recombinant antigens such as Env-SU may
be considered as payloads for PLGA nanoparticles. Antigen release
characteristics are influenced by particle size, polymer composition, antigen
properties, and environmental conditions. With appropriate optimization, PLGA
has the potential to maintain antigen availability and regulate its
interactions with antigen-presenting cells.
Nevertheless, sustained antigen release does not
automatically replace the function of booster vaccination. Long-lasting immune
responses require adequate antigenic stimulation, the development of
immunological memory cells, and appropriate regulation of immune responses.
Therefore, the claim that a single PLGA-based vaccine dose could replace two
conventional vaccination doses must be demonstrated through experimental
comparisons with conventional vaccination schedules.
Furthermore, PLGA formulations must address potential
antigen degradation during manufacturing and storage, encapsulation efficiency,
and antigen release profiles. These parameters are essential for maintaining
product quality consistency.
3.3.3. Chitosan Nanoparticles
Chitosan is a polymer derived from chitin that possesses
positively charged functional groups under certain conditions. These
physicochemical properties enable interactions with negatively charged
molecules, making chitosan a potential material for the delivery of both
antigens and nucleic acids.
Chitosan has potential applications in the formulation of
mucosally administered vaccines. Its mucoadhesive properties may help retain
formulations on mucosal surfaces; however, delivery performance depends on
particle size, surface charge, solubility, mucus characteristics, and the
biological conditions at the administration site.
For JDV vaccine development, chitosan-based formulations
can be investigated as alternatives to parenteral administration. However,
intranasal or oral administration cannot be considered more effective solely on
the basis of chitosan's mucoadhesive properties. Their effectiveness must be
demonstrated through the assessment of mucosal immune responses, tissue safety,
systemic immune responses, and protection against disease.
Chitosan is also not necessarily stable or optimally
soluble under all physiological conditions. Therefore, its composition, raw
material characteristics, and final product quality must be standardized before
further development for veterinary applications.
3.4. Mechanisms of Immune Response Enhancement
One of the objectives of developing nanotechnology-based
vaccines is to improve antigen uptake by antigen-presenting cells, including
dendritic cells. These cells process antigens and present them through major
histocompatibility complex (MHC) molecules to T lymphocytes, thereby linking
innate immune responses with adaptive immune responses.
3.4.1. Antigen Presentation through MHC-I and MHC-II
Antigens produced intracellularly, for example following
mRNA vaccine administration, can be processed through the major
histocompatibility complex class I (MHC-I) presentation pathway for recognition
by CD8+ T cells. Activated CD8+ T cells can contribute to the recognition and
control of cells expressing the corresponding antigens.
Meanwhile, antigens taken up from the extracellular
environment are generally processed through the MHC class II (MHC-II) pathway
to activate CD4+ T cells. Some extracellular antigens may also enter the MHC-I
cross-presentation pathway, depending on antigen properties, the type of
antigen-presenting cell, and the characteristics of the delivery system.
Nanoparticles can influence these processes through their
size, surface charge, composition, and distribution patterns within tissues.
However, particle sizes resembling those of viral particles do not, by
themselves, guarantee effective antigen cross-presentation.
In the context of JDV vaccines, the success of this
approach should be evaluated by assessing T-cell activation profiles, cytokine
production, antibody responses, and relevant indicators of protection. Even
strong cellular immune responses must be interpreted alongside safety data and
clinical outcomes.
3.4.2. Activation of Innate Immunity
The innate immune system recognizes various molecular
signals through pattern recognition receptors (PRRs). Activation of specific
signaling pathways can promote the production of cytokines and interferons,
which help shape the development of adaptive immune responses.
Certain components of nucleic acid-based vaccines may
influence innate immune recognition; however, the activation of specific
pathways cannot be assumed solely because a formulation incorporates
nanoparticles. These effects depend on material composition, cargo
characteristics, delivery location, and the types of cells exposed to the
formulation.
Toll-like receptor (TLR) and cyclic GMP-AMP
synthase–stimulator of interferon genes (cGAS-STING) pathways are examples of
immune recognition systems relevant to vaccinology. However, these pathways
involve distinct recognition and activation mechanisms. The cGAS-STING pathway
is primarily associated with the recognition of DNA in the cytosol, whereas RNA
recognition involves other receptors and mechanisms, depending on the molecular
characteristics of the RNA.
Therefore, the selection of adjuvants and delivery
systems for JDV vaccines should be based on the intended immune response and
experimental findings, rather than on the assumption that all nanoparticles
activate the same immune signaling pathways.
3.5. Comparison of JDV Vaccine Development Strategies
The following comparison describes the general
characteristics of each platform and does not represent the results of direct
comparative trials against JDV (Table 1).
Table 1. Comparative Characteristics of Different Vaccine
Platforms for Jembrana Disease Virus (JDV) Development
|
Parameter |
Inactivated
Tissue-Based Vaccine |
PLGA/Chitosan-Based
Subunit Vaccine |
LNP-Based
Nucleic Acid Vaccine |
|
Antigen
source |
Processed
animal-derived biological materials from tissues or plasma |
Recombinant
antigens produced under controlled conditions |
mRNA or
DNA encoding selected antigens |
|
Biological
safety |
Requires
validated inactivation procedures and control of adventitious agents |
Does
not require intact virus; antigen quality must still be controlled |
Does
not require replication-competent JDV |
|
Immune
response |
Can
induce antibody responses and clinical protection |
Has the
potential to induce humoral responses; cellular responses depend on the
formulation |
Has the
potential to induce both humoral and cellular immune responses |
|
Antigen
release |
Depends
on vaccine formulation and its characteristics |
Can be
engineered to regulate antigen release |
Depends
on nucleic acid stability and antigen expression |
|
Stability |
Determined
by formulation and storage conditions |
Depends
on the polymer, antigen, and manufacturing process |
Depends
on nucleic acid design and LNP composition |
|
Scalability |
Depends
on the availability of biological materials and processing procedures |
Potentially
scalable through recombinant production and standardized formulation
processes |
Potentially
scalable through nucleic acid synthesis and formulation processes |
|
Major
challenges |
Raw
material consistency, inactivation validation, and quality control |
Antigen
stability, encapsulation efficiency, and release consistency |
Storage
stability, cost, and delivery efficiency |
|
Status
for JDV |
Already
implemented, with evidence of beneficial effects |
Requires
further development and JDV-specific validation |
Requires
further development and JDV-specific validation |
Source:
Hartaningsih et al. (2001), Ditcham et al. (2009), Desport and Lewis (2010),
and Schoenmaker et al. (2021).
This comparison demonstrates that each platform has its
own advantages and limitations. Tissue-based vaccines have direct evidence of
benefits against Jembrana disease, whereas nanotechnology-based platforms offer
opportunities to improve production consistency and modulate immune responses.
Therefore, replacing currently used vaccines should be based on evidence
demonstrating that new candidates meet, at a minimum, the required standards of
safety, quality, and efficacy.
3.6. Challenges in Development and Translation to
Practical Application
3.6.1. Standardization of Physicochemical Characteristics
Nanoparticle characterization is an essential component
of quality control. Key parameters include particle size, size distribution,
polydispersity index (PDI), surface charge or zeta potential, encapsulation
efficiency, antigen content, and storage stability.
Mean particle size alone is insufficient to describe
formulation quality. A broad particle-size distribution may affect product
consistency, whereas changes in zeta potential may provide information about
colloidal stability under specific testing conditions.
Encapsulation efficiency should also be distinguished
from the amount of antigen that retains its biological activity. Although an
antigen may be successfully incorporated into nanoparticles, structural
alterations may occur that reduce its immunological recognition. Therefore,
physicochemical characterization should be accompanied by methods for
evaluating antigen integrity and biological activity.
3.6.2. Stability and the Cold Chain
Stability is a critical factor in the practical
application of vaccines in Indonesian livestock production systems.
Temperature, humidity, light exposure, transportation conditions, and storage
duration can all affect product quality.
LNP-mRNA vaccines face challenges related to nucleic acid
stability and nanoparticle structural integrity. Certain formulations require
low-temperature storage, although the development of stabilization and drying
methods continues to be investigated (Schoenmaker et al., 2021).
Meanwhile, the use of PLGA and chitosan does not
automatically guarantee improved stability under tropical conditions. Stability
must still be demonstrated through appropriate real-time and accelerated
testing, including assessments of vaccine potency after storage and simulated
distribution conditions.
3.6.3. Production Costs and Scalability
Veterinary vaccines must take into account the cost per
dose, ease of production, availability of raw materials, and distribution
capacity. Recombinant and nucleic acid-based platforms have the potential to
reduce dependence on animal-derived biological materials. However, synthesis,
purification, formulation, and quality control costs may represent substantial
components of overall production costs.
Chitosan may be an attractive material for further
investigation because of its properties as a natural polymer, whereas PLGA
offers flexibility in controlling cargo release. Nevertheless, material
selection should not be based solely on raw material prices. Overall processing
costs, batch-to-batch consistency, product stability, and the need for booster
doses must also be considered.
An economic feasibility assessment is therefore essential
to determine whether a particular platform can be practically implemented in a
nationwide vaccination program for Bali cattle.
3.6.4. Safety and Regulatory Requirements
The development of nanotechnology-based vaccines requires
comprehensive safety assessments, including local tolerability, systemic
reactions, potential adverse effects of the delivery materials, and the safety
of repeated administration. For nucleic acid-based vaccines, the evaluation
should also address antigen expression characteristics and biological risks
relevant to the specific product design.
Vaccines that do not contain intact JDV particles offer
the advantage of reducing dependence on the handling of whole viruses during
the manufacturing process. However, this characteristic does not automatically
imply that the resulting products are risk-free. The overall safety profile
must be established through appropriate testing in accordance with the vaccine
type and the requirements of the relevant veterinary regulatory authorities.
3.7. Recommended Research and Development Stages
The development of nanotechnology-based JDV vaccines
should follow a phased approach to ensure that scientific decisions and
investment strategies are based on verifiable evidence.
The first stage involves antigen selection and biological
feasibility assessment. At this stage, Env-SU and other potential antigen
candidates should be evaluated based on their immunological relevance, epitope
conservation, and potential to induce immune responses associated with
protection.
The second stage involves formulation development and
quality characterization. Candidates based on PLGA, chitosan, or lipid
nanoparticles (LNPs) should be compared in terms of their physicochemical
properties, antigen integrity, delivery efficiency, and stability. Platform
selection should be guided by experimental findings rather than the assumption
that one material is inherently superior to another.
The third stage involves the evaluation of immunogenicity
and preclinical safety using appropriate experimental systems. Assessments may
include antibody responses, neutralizing activity where validated methods are
available, cellular immune response profiles, and relevant safety indicators.
The fourth stage involves evaluation in Bali cattle
through research designs that comply with ethical, biosafety, and regulatory
requirements. These studies should be designed to compare vaccine candidates
against appropriate controls and, where relevant, currently used comparator
vaccines. Sample sizes, predefined success criteria, and statistical analysis
plans should be established before the studies commence.
The fifth stage involves production assessment and
implementation feasibility evaluation. Key aspects to be analyzed include
batch-to-batch consistency, cost per dose, stability during distribution, user
acceptance, and the need to strengthen disease surveillance and control
systems.
The overall success of the development program should not
be determined solely by the magnitude of antibody responses. Vaccine candidates
must demonstrate an acceptable safety profile and meaningful protective
benefits against the disease, supported by consistent manufacturing quality.
4. CONCLUSION
Nanotechnology offers strategic opportunities for the
development of Jembrana disease virus (JDV) vaccines as an alternative to, or
an improvement upon, existing tissue-based inactivated vaccines. Lipid
nanoparticle (LNP) platforms have the potential to facilitate nucleic acid
delivery and intracellular antigen expression, whereas poly(lactic-co-glycolic
acid) (PLGA) and chitosan nanoparticles can be investigated for antigen
protection and modulation of delivery characteristics.
Env-SU represents a relevant antigen candidate for
inducing antibody responses against viral envelope proteins, while Tat may be
investigated as a potential antigen source for eliciting cellular immune
responses, with due consideration given to its safety and biological relevance.
The combination of antigens and nanoparticle-based delivery systems may support
the development of both humoral and cellular immune responses. However, the
magnitude and protective benefits of these responses remain to be specifically
demonstrated for JDV.
The major challenges in vaccine development include
standardization of physicochemical properties, storage stability, production
costs, biological safety, and demonstration of efficacy in Bali cattle.
Therefore, research should be conducted through a phased approach, beginning
with antigen selection and formulation characterization, followed by
immunogenicity evaluation and subsequent safety and protective efficacy studies
in the target animal species.
Through an evidence-based approach, the development of
nanotechnology-based JDV vaccines has the potential to strengthen Indonesia's
self-reliance in veterinary vaccine production, support Jembrana disease
control, and contribute to the conservation and sustainability of Bali cattle
populations as a valuable national livestock genetic resource.
5. REFERENCES
Desport, M., & Lewis, J. (2010). Jembrana disease
virus: Host responses, viral dynamics and disease control. Current HIV
Research, 8(1), 53–65. https://doi.org/10.2174/157016210790416370
Ditcham, W. G. F., Lewis, J. R., Dobson, R. J.,
Hartaningsih, N., Wilcox, G. E., & Desport, M. (2009). Vaccination reduces
the viral load and the risk of transmission of Jembrana disease virus in Bali
cattle. Virology, 386(2), 317–324. https://doi.org/10.1016/j.virol.2009.02.008
Hartaningsih, N., Dharma, D. M., Soeharsono, S., &
Wilcox, G. E. (2001). The induction of a protective immunity against Jembrana
disease in cattle by vaccination with inactivated tissue-derived virus
antigens. Veterinary Immunology and Immunopathology, 78(2), 163–176. https://doi.org/10.1016/S0165-2427(00)00265-8
Schoenmaker, L., Witzigmann, D., Kulkarni, J. A.,
Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. A. (2021).
mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. International
Journal of Pharmaceutics, 601, 120586. https://doi.org/10.1016/j.ijpharm.2021.120586
#JembranaVaccine
#Nanotechnology
#BaliCattle
#JDV
#AnimalHealth








